OABI · OmniAb

The thesis

OmniAb is modestly more likely to beat the S&P 500 over the next three months. Its raised 2026 guidance and $8.3 million of operating cash inflow over nine months show that partners can fund its antibody-discovery model. The case depends on partner milestone payments resuming after a quiet third quarter. The fourth-quarter report, expected around early March 2027, shows whether they did through its milestone revenue and any 2027 outlook.

The shares closed at $4.95 on 12 November 2026, up 46.4% over three months from $3.38 on 14 August 2026 and far above the 52-week closing low of $1.36 on 29 April 2026. At that price the market already reflects the 30 October 2026 guidance raise and the August Eli Lilly deal. Further gains need a new partner milestone or a 2027 outlook that keeps revenue near 2026 levels.

The cash figures come from the 10-Q for the quarter to 30 September 2026. Operating activities brought in $8.3 million over nine months, against $30.8 million used a year earlier. On the 30 October 2026 call, management described 2026 as "basically break-even" on net cash flow, per MarketBeat's summary. A fiscal.ai headline on 2 November 2026 called this "self-sustaining cash flow", which goes further than management did. Year-end cash guidance of $53–57 million is below the $64.2 million held on 30 September 2026, so the company expects cash to fall in the fourth quarter.

The rating is Medium. The filed cash flow and the guidance raise support the case, but the third quarter brought almost no milestone revenue, so the case is not yet proven. Two quarters with very different milestone revenue are too few to set a run-rate.

Bullish and bearish views on OmniAb, Inc.

The bull case on OmniAb, Inc. (OABI), in brief: operating cash flow turned positive. The bear case: milestone revenue nearly vanished last quarter.

Bull case

• Operating cash flow turned positive. Operating activities brought in $8.3 million in the nine months to 30 September 2026, against $30.8 million used a year earlier, per the 10-Q. The main driver was an $11.7 million increase in deferred revenue.
• The Lilly deal brings cash into later years. OmniAb announced an ion-channel collaboration with Eli Lilly on 17 August 2026. GuruFocus's summary of the 30 October 2026 call puts potential milestones at up to $370 million. The 10-Q describes a nonrefundable $12.5 million upfront payment under an August 2026 agreement. Deferred revenue on 30 September 2026 was $5.2 million current and $9.7 million long-term.
• Guidance rose on 30 October 2026. The third-quarter release moved full-year 2026 revenue guidance to $35–39 million from $32–36 million. Year-end cash guidance moved to $53–57 million from $49–53 million.
• Nine months already approach the guidance. Revenue for the nine months to 30 September 2026 was $31.835 million, including $21.64 million of license and milestone revenue, per the third-quarter release. Third-quarter revenue alone was $3.993 million, against $2.239 million a year earlier.
• Partner programs keep advancing. China's drug regulator approved batoclimab from Harbour BioMed and NBP Pharma on 22 October 2026. Management called it the fourth approved drug from OmniAb's platform, per MarketBeat. On 30 September 2026, OmniAb counted 111 active partners, 433 active programs and 34 clinical or commercial programs, with about $340 million of remaining potential clinical milestones.

Bear case

• Milestone revenue nearly vanished last quarter. Third-quarter license and milestone revenue was $100,000, per the 30 October 2026 release, against $21.64 million over nine months. A few partner events produced most of the year's revenue.
• GAAP losses continue. OmniAb lost $15.7 million in the third quarter of 2026 on revenue of $3.993 million, per the release. The positive operating cash flow relies on upfront payments booked as deferred revenue.
• Cash is guided to fall. Year-end cash guidance of $53–57 million compares with $64.2 million on 30 September 2026, per the third-quarter release.
• Share sales remain an option. The $100 million at-the-market agreement with Jefferies, signed in December 2023, is still in place. The 10-Q reports no sales under it in the nine months to 30 September 2026 and 145,860,318 shares outstanding on 23 October 2026. OmniAb also announced a $30 million private placement in August 2025.
• The price ran ahead of new facts. The shares hit an intraday 52-week high of $5.45 on 9 November 2026 without any company release after the 2 November 2026 cash-flow headline. The only filing since is a director's Form 4 reporting an option exercise of 13,334 shares on 1 November 2026.

Price setup

The shares closed at $4.95 on 12 November 2026, 9.2% below the intraday 52-week high of $5.45 on 9 November 2026. The highest close in that run was $5.30 on 9 November 2026. Closes between 5 November 2026 and 12 November 2026 ranged from $4.83 on 5 November 2026 to $5.30, and the shares have closed lower in two of the three sessions since the high.

On 12 November 2026 the 50-day moving average stood at $4.74 and the 200-day at $2.84, both below the last close. A close under the 50-day average would show the gains since the third-quarter report fading. The latest advance began from the close on 6 October 2026, the day of OmniAb's Analyst Day, where the company set out its multi-year outlook.

No earnings date falls in the next 30 days. The open at-the-market agreement lets the company sell shares into strength, and any such sales would appear in a filing or release.

Catalysts ahead

• 16 November 2026: Jefferies London Healthcare Conference, through 19 November 2026. Management meets investors after the third-quarter report and could update the timing of partner milestones, which drive the case.
• 17 November 2026: Craig-Hallum Investor Conference. This is the last of OmniAb's announced November investor meetings before the year-end test of its guided revenue and cash figures.
• ~4 March 2027 (est.): Fourth-quarter and full-year 2026 results. The report shows whether revenue lands within $35–39 million, whether year-end cash meets $53–57 million and whether milestone payments resumed.

What would change the view

A daily close below $4.35, the 6 October 2026 Analyst Day close, which would erase the gains since the multi-year outlook. Full-year 2026 revenue below $35 million, or an equity offering, would also break the case.

The risks this note tracks, each with what would confirm it:

• Partner milestone payments stay near zero, as in the third quarter, so 2027 revenue falls back toward service and royalty levels. Confirmed by: fourth-quarter license and milestone revenue near the third quarter's $100,000, or 2027 guidance below 2026 revenue.
• Full-year 2026 results miss the raised guidance. Confirmed by: reported 2026 revenue below $35 million or year-end cash below $53 million in the fourth-quarter release.
• Equity issuance dilutes shareholders while GAAP costs exceed revenue, more likely with the shares near a 52-week high. Confirmed by: an offering, private placement or at-the-market sales disclosure in an SEC filing or company release.
• A key partner program fails, cutting the expected milestone and royalty stream. Confirmed by: a negative IMVT-1402 update from Immunovant or a discontinued OmniAb-derived clinical program.
• The shares give back the gains since the third-quarter report without new partner news. Confirmed by: closes back under the 50-day moving average with no partner milestone or deal announced by year-end 2026.

What it trades with

OmniAb's revenue depends on partner events, including Eli Lilly's ion-channel program, Immunovant's IMVT-1402 and Harbour BioMed's batoclimab. News from those partners' trials can move the shares more than the broad market does. As a small, loss-making biotech platform company, OmniAb tends to trade with funding conditions for small biotech companies. Its partners' spending on discovery licenses ties the business to large-pharma research budgets more than to the direction of the S&P 500.